Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial
<h3>Background</h3><p dir="ltr">The pandemic of COVID-19 infection has emerged as a rapidly spreading communicable disease across the globe. Patients with diabetes mellitus are at a higher risk of mortality from COVID-19, mainly due to the chronic. inflammatory state asso...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , , , , , , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513515116560384 |
|---|---|
| author | Eman Elmekaty (14777932) |
| author2 | Khaled Baagar (7487690) Amin Jayyousi (3158868) Thamer Alessa (10534630) Muhammad Abdul-Ghani (4707436) Mohamed Abu-Farha (25322) Ali Senosi Omrani (18505373) Jose Ceruto (18505376) Mohammad Khair Hamad (18505379) Muhammad Zaka-Ul Haq (18505380) Abdul Safi, Bassem Alhariri (18505381) Manish Barman (18505384) Alaaeldin Abdelmajid (12535542) Pioglitazone and COVID-19 study group (18505385) |
| author2_role | author author author author author author author author author author author author author |
| author_facet | Eman Elmekaty (14777932) Khaled Baagar (7487690) Amin Jayyousi (3158868) Thamer Alessa (10534630) Muhammad Abdul-Ghani (4707436) Mohamed Abu-Farha (25322) Ali Senosi Omrani (18505373) Jose Ceruto (18505376) Mohammad Khair Hamad (18505379) Muhammad Zaka-Ul Haq (18505380) Abdul Safi, Bassem Alhariri (18505381) Manish Barman (18505384) Alaaeldin Abdelmajid (12535542) Pioglitazone and COVID-19 study group (18505385) |
| author_role | author |
| dc.creator.none.fl_str_mv | Eman Elmekaty (14777932) Khaled Baagar (7487690) Amin Jayyousi (3158868) Thamer Alessa (10534630) Muhammad Abdul-Ghani (4707436) Mohamed Abu-Farha (25322) Ali Senosi Omrani (18505373) Jose Ceruto (18505376) Mohammad Khair Hamad (18505379) Muhammad Zaka-Ul Haq (18505380) Abdul Safi, Bassem Alhariri (18505381) Manish Barman (18505384) Alaaeldin Abdelmajid (12535542) Pioglitazone and COVID-19 study group (18505385) |
| dc.date.none.fl_str_mv | 2024-05-26T04:56:16Z |
| dc.identifier.none.fl_str_mv | 10.57945/manara.25709406.v1 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/conference_contribution/Pioglitazone_Effect_on_Clinical_Outcome_and_Inflammatory_Response_in_patients_with_type_2_diabetes_mellitus_and_COVID-19_A_Randomized_Clinical_Trial/25709406 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Diabetes Mellitus Pioglitazone RCT Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| dc.title.none.fl_str_mv | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| dc.type.none.fl_str_mv | Text Conference contribution info:eu-repo/semantics/publishedVersion text conference object |
| description | <h3>Background</h3><p dir="ltr">The pandemic of COVID-19 infection has emerged as a rapidly spreading communicable disease across the globe. Patients with diabetes mellitus are at a higher risk of mortality from COVID-19, mainly due to the chronic. inflammatory state associated with diabetes. It was hypothesized that Pioglitazone - a medicine used to treat diabetes with proven anti-inflammatory properties – may improve COVID-19 outcomes in patients with diabetes. The aim of this study was to evaluate the efficacy of pioglitazone in improving the clinical outcomes of patients with type 2 diabetes (T2D) admitted with moderate-severe COVID-19.</p><h3>Methods</h3><p dir="ltr">Eligible patients with T2D and admitted with COVID-19 to the hospitals in Qatar and Kuwait were randomized in a double-blind fashion to receive either pioglitazone 45mg orally daily for 10 days then 30mg daily for 18 days or a matching placebo. The study had 2 primary outcomes: (1) the incidence of a clinical composite outcome of a) requirement for mechanical ventilation, b) death, c) myocardial damage indicated by Troponin > 3x upper limit of normal range; and 2) an increase in C-reactive protein (CRP). Blood samples were collected at baseline and repeated weekly until day 28 or discharge.</p><h3>Results</h3><p dir="ltr">Total of 343 patients, pioglitazone (n=188) and placebo (n=155), were enrolled in the study. Twenty-eight participants met the primary clinical composite outcome. There was no significant difference in the incidence of primary outcome between subjects receiving placebo (n=14) and pioglitazone (n=14). Cox Hazard ratio for patients receiving pioglitazone was 1.10 (p=NS). A total of 4 patients died in the placebo group vs. 3 in the pioglitazone group (p =0.91). No statistically significant difference was observed between the two groups in plasma CRP level at the end of the follow-up.</p><h3>Conclusion</h3><p dir="ltr">Pioglitazone treatment did not provide any additional clinical benefit to patients with T2D admitted with COVID-19 infection.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_2901438cbbaa51d276aa52bd46219734 |
| identifier_str_mv | 10.57945/manara.25709406.v1 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25709406 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical TrialEman Elmekaty (14777932)Khaled Baagar (7487690)Amin Jayyousi (3158868)Thamer Alessa (10534630)Muhammad Abdul-Ghani (4707436)Mohamed Abu-Farha (25322)Ali Senosi Omrani (18505373)Jose Ceruto (18505376)Mohammad Khair Hamad (18505379)Muhammad Zaka-Ul Haq (18505380)Abdul Safi, Bassem Alhariri (18505381)Manish Barman (18505384)Alaaeldin Abdelmajid (12535542)Pioglitazone and COVID-19 study group (18505385)Biomedical and clinical sciencesCardiovascular medicine and haematologyClinical sciencesPharmacology and pharmaceutical sciencesCoronavirusCOVID-19Diabetes MellitusPioglitazoneRCTQatar Health Congress 2023 and the 3rd Qatar Public Health Conference<h3>Background</h3><p dir="ltr">The pandemic of COVID-19 infection has emerged as a rapidly spreading communicable disease across the globe. Patients with diabetes mellitus are at a higher risk of mortality from COVID-19, mainly due to the chronic. inflammatory state associated with diabetes. It was hypothesized that Pioglitazone - a medicine used to treat diabetes with proven anti-inflammatory properties – may improve COVID-19 outcomes in patients with diabetes. The aim of this study was to evaluate the efficacy of pioglitazone in improving the clinical outcomes of patients with type 2 diabetes (T2D) admitted with moderate-severe COVID-19.</p><h3>Methods</h3><p dir="ltr">Eligible patients with T2D and admitted with COVID-19 to the hospitals in Qatar and Kuwait were randomized in a double-blind fashion to receive either pioglitazone 45mg orally daily for 10 days then 30mg daily for 18 days or a matching placebo. The study had 2 primary outcomes: (1) the incidence of a clinical composite outcome of a) requirement for mechanical ventilation, b) death, c) myocardial damage indicated by Troponin > 3x upper limit of normal range; and 2) an increase in C-reactive protein (CRP). Blood samples were collected at baseline and repeated weekly until day 28 or discharge.</p><h3>Results</h3><p dir="ltr">Total of 343 patients, pioglitazone (n=188) and placebo (n=155), were enrolled in the study. Twenty-eight participants met the primary clinical composite outcome. There was no significant difference in the incidence of primary outcome between subjects receiving placebo (n=14) and pioglitazone (n=14). Cox Hazard ratio for patients receiving pioglitazone was 1.10 (p=NS). A total of 4 patients died in the placebo group vs. 3 in the pioglitazone group (p =0.91). No statistically significant difference was observed between the two groups in plasma CRP level at the end of the follow-up.</p><h3>Conclusion</h3><p dir="ltr">Pioglitazone treatment did not provide any additional clinical benefit to patients with T2D admitted with COVID-19 infection.</p>2024-05-26T04:56:16ZTextConference contributioninfo:eu-repo/semantics/publishedVersiontextconference object10.57945/manara.25709406.v1https://figshare.com/articles/conference_contribution/Pioglitazone_Effect_on_Clinical_Outcome_and_Inflammatory_Response_in_patients_with_type_2_diabetes_mellitus_and_COVID-19_A_Randomized_Clinical_Trial/25709406CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/257094062024-05-26T04:56:16Z |
| spellingShingle | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial Eman Elmekaty (14777932) Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Diabetes Mellitus Pioglitazone RCT Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |
| status_str | publishedVersion |
| title | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| title_full | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| title_fullStr | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| title_full_unstemmed | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| title_short | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| title_sort | Pioglitazone Effect on Clinical Outcome and Inflammatory Response in patients with type 2 diabetes mellitus and COVID-19: A Randomized Clinical Trial |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Pharmacology and pharmaceutical sciences Coronavirus COVID-19 Diabetes Mellitus Pioglitazone RCT Qatar Health Congress 2023 and the 3rd Qatar Public Health Conference |